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CD8 is a T lymphocyte surface glycoprotein expressed on most thymocytes and
by class I MHC molecules (1).
ion. A large body of evidence
of CD8 is to increase the avidity of
the interaction between the T cell and target or APC and to enhance T cell activa-
tion, most likely by binding to a nonpolymorphic (or relatively nonpolymorphic)
region of class I MHC proteins (1-7). Biochemical and molecular genetic studi
have demonstrated that mouse (Ly-2,3) and rat (OX-8) CD8 consist ofheterodimers
(and higher multimers) of two distinct polypeptides (a and 0) encoded by separate
genes (8-14). In contrast, human CD8 has been consistently described on
T cells as a homodimer or homomultimer of a single polypeptide chain (15, 16) ho-
mologous to mouse Ly-2a or rat OX-8 32K (C138a) (10, 11, 13). This apparent differ-
ence in subunit composition is surprising for a molecule whosecellular distribution
and functional role is so well conserved among these three species. A human gene
homologous to mouse Ly-3 and rat C*68 37K (CD80) chains was recently identified
and partially sequenced (17). mRNA corresponding to this gene was shown to be
present in human thymus as well as a human leukemic T cell line (HPB-ALL), but
the limited data did not allow any conclusions as to whether a protein could be ex-
pressed (17). We now report the isolation ofcDNA clones encoding a second chain
(CD80) of the human CD8 antigen. Using the mAb 2STS5117, we show expres-
sion ofthe encoded protein on L cell transfectants and on normal human peripheral
blood cells in conjunction with the CD8a chain. Its expression is limited to OKT8'
cells, suggesting that human CD8, like its mouse and rat counterparts, also exists
as a heterodimer.
cells that reco
Most such cells are cytotoxic or suppress
now supports the hypothesis that the fun
cDXA Cloning andSequencing.
￿
A rat CD80 cDNA clone (pX9.5, reference 14) was labeled
with "P by random hexamer priming (18) and used to screen a human thymocyte cDNA
library in the vector XgUO. Filters were hybridized as described (10) and washed (30 min each)
SSC, 0.05% SDSj at room temperature, once in I x SSC, 0.05% SDS at 371C,
0.5 x SSC, (h{)5% SDS at 42'C. Six hybridizing clones were selected based on
(1.3 kb or larger), subcloned into M13, and sequenced using the Sequenase system
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EXPRESSION OF HUMAN CD80
(United States Biochemical Corp., Cleveland, OH). Both strands ofall six clones were com-
pletely sequenced. The genomic subdone p7,4.3 (17) was similarly subcloned and sequenced.
Northern Blotting Analysis. Total RNA from cell lines, tissue, or PBMC was isolated by
the procedure of Chirgwin et al. (19). 10 Rg of each sample was subjected to electrophoresis
through a 1 .5% agarose gel containing 2.2 M formaldehyde. The RNA was transferred to
Genetran 45 (Plasco) and hybridized to a human CD80 cDNA fragment labeled with 32p
by random hexamer priming (18). Hybridization was performed at 42 °C in 3x SSC, 2%
SDS, 5 x Denhardt's solution, 0.02 M sodium phosphate, 1 mM pyrophosphate, 100 Rg/ml
denatured herring sperm DNA, 100 ug poly C, and 50% formamide. Blots were washed as
described (10).
Construction and Tmnsfection ofpSFSVn-HCD8.
￿
An expression vectorcontaining the sequence
encoding human CD8p was constructed by isolating the Eco RI-Rsa I fragment of a cDNA
clone that contained the entire coding region and most ofthe 3' untranslated region ofhuman
CD8p. The Eco RI end was blunt ended and the resulting 1.37-kb fragment subcloned into
the blunt-ended Xho I site of the pSFSVneo vector (20). A clone in the orientation allowing
transcription of sense mRNA was selected and designated pSFSVn-HCD8p. 106 thymidine
kinase (tk)' deficient L cells were cotransfected as described (21) with 1 ug of PSFSVn-
HCD8p and 20 kg of pBR322/TK/CD8a (a vector containing the human CD8a gene, refer-
ence 12) or 1 Rg ofpSFSVn-HCD8p and 20 kg oftk- L cell carrier DNA. Transfectants were
selected by growth in 300 wg/ml G418 (Gibco Laboratories, Grand Island, NY) for 2-3 wk
and then analyzed with the FACS.
Cells and Culture Conditions.
￿
Peripheral blood from a healthy donor was mixed with an
equal volume of RPMI containing 10% FCS and separated on Histopaque-1077 (Sigma Chem-
ical Co., St. Louis, MO). The mononuclear cells were recovered, washed repeatedly to re-
move platelets, and resuspended for staining. L cell transfectants were cultured in high glu-
cose DME (Irvine Scientific, Santa Ana, CA) containing 5 % FCS and the appropriate selective
medium. The HPB-ALL cell line was cultured in RPMI 1640 (Irvine Scientific) supplemented
with 10% FCS.
Immunofluorescence and Flow Cytometry.
￿
Antibody stainings were performed sequentially in
PBS with 1% BSA and 0.02% sodium azide. Flow cytometry and data analysis were per-
formed using either a single or dual laser-modified FACS (FACS II; Becton Dickinson &
Co., Mountain View, CA).
Results
Isolation ofHuman CD8P cDNA Clones.
￿
We screened a human thymocyte cDNA
library with a cDNA probe corresponding to rat CD80 (14) and determined the
nucleotidesequence ofsix ofthe isolated clones. Each contained a single open reading
frame. The nucleotide and predicted amino acid sequences corresponding to four
of these clones are shown in Fig. 1. The sequences predict a mature protein of 189
amino acids (predicted mol wt, 21,353), with an external domain of 143 amino acids,
a hydrophobic transmembrane region of 27 amino acids, and a highly basic cyto-
plasmic tail of 19 amino acids. There is one potential N-linked glycosylation site
at aminoacid 81 . The mature protein is preceded by a 21-amino acid signal peptide.
As shown in Fig. 2, the amino acid sequence of mature human CD80 is 57% iden-
tical to both mouse (12, 22, 23) and rat (14) CD8a . The sequence is not closely related
to that of human CD8a, with only 25% identical residues with numerous gaps in
the alignment (data not shown). As has been previously observed (12, 14, 17, 22,
23), CD80 is a member of the Ig gene superfamily and contains NH2-terminal do-
mains homologous to Ig variable (V) regions and joining (J) segments. These Ig-
like regions are connected to the membrane by a 29-amino acid connecting peptide
I Abbreviation used in this paper: tk, thymidine kinase.SHIUE ET AL. 1995
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Comparison of predicted amino acid sequences of human, mouse, and rat CD8p.
Amino acids are designated by the one letter code. Identical residues are indicated by asterisks
and gaps in thealignment are indicatedby hyphens. The domains of the proteins areindicated
by horizontal arrows and labeled as in Fig. 1. The numbers of the first and last amino acids
in each line are indicatedin the left and right margins, respectively. CD80 sequences are from
this studyforhuman, from reference 12 formouse, andfrom reference14 forrat. These sequence
data have been submited to the EMBL/GenBank Data Libraries under the accession number
Y00805.
that is not homologous to other known proteins, except themouse and rat homologs
(Figs. 1 and 2).
Alternative Splicing Yields a Human CD8fl mRNA Encoding a Longer Cytoplasmic Tail.
Twoofthe six cDNA clones sequenced contain an additional 58 by locatedat a posi-
tion (between nucleotides 665 and 666) corresponding in the gene to the 3' end of
the exon encoding most of the cytoplasmic tail (Fig. 3). This insertion changes the
readingframe, thereby altering the predicted cytoplasmic tail amino acid sequence
and termination codon, and extending thelength of the predicted protein sequence
by 36 amino acids (predicted molwt, 25,327). To determine the mechanism accounting
for this additional mRNA species, we sequenced a genomic subclone containing
the last exon of the gene and encoding the COOH terminus of the cytoplasmic tail
and the 3' untranslated region. This portion of the gene had not been previously
sequenced. We found that the additional 58 nucleotides derive from utilization of
an imperfect alternative splicing acceptor site at the 5' end of this exon (Fig. 3). S1
nuclease studies indicate that thereis a substantial amount ofthis alternative mRNA
species present in human thymus RNA (data not shown).
Polymorphism ofHuman CD80.
￿
Southern blot analysis has shown the presence of
asingle, nonrearranging CD8p gene in thehuman genome (datanot shown). How-
ever, our cDNA clones (derived from a single individual) represent two sets of se-
quences with three nucleotides changes between them (Fig. 1), so these sequences
must correspond to two separate alleles of CD80. Two of these changes are in the
3' untranslated region, while one is in the transmembrane region and results in an
amino acid substitution at position 159 (Val to Ile) . In comparing our cDNA se-
quences with both the published partial genomic sequence (17) and our additional
genomic sequence (Fig. 3), we find three additional polymorphisms (nucleotides 556,
618, and 677), two ofwhich result in aminoacid substitutions in thetransmembrane
1996 EXPRESSION OF HUMAN CD80
F-~L F--+v
Human -21 NRPRLWLLLAAQLTVLHGNSVLQQTPAYIKVQTNIQlVMISCEAK-ISISNNRIYWLRQR 37
Mouse -21 *Q*W***VFSMK*AA*WSS*A*I***SSLL****HTAKM***V*S**-KLTS*****E* 37
Rat -21 *Q*W***VFSVK*SA*W*S*A*L***SSLL****QTAKN*****-TFPKGTT*****EL 37
Human 38 QAPSSDSHHEFLALWDSAKGTIHGEEVEQEK-IAVFRDASR-FILNLTSVKPEDSGIYF 94
Mouse 38 *D*-K*KYF****S*S*S**VLY**S*DKKRN*ILESSD**RPF*SINN******DF** 95
Rat 38 *DSNKNK*F****SRT*T**IKY**R*-KK-NMTL-SFN*TLPF*KIMD*******F** 93
f---+~7 F--yCP F-'"TM
Human 95 CMIVGSPDLTFGKGTQLSVVDFLPTTAQPTKKSTLK---KRVCRLPRPETQKGPLCSPI 150
Mouse 96 *AT****KMV**T**K*T***V*****-****T+**MKK*KQ*PF*H******LT**LT 153
Rat 94 *AM****MVV**T**K*T***V*****-****T***---*KQ*PT*H*K****LT*GL* 149
E--CY
Human 151 TLGLLVAGVLVLLVSLGVAIHLCCRRRRARLRFMKQFYK 189
Mouse 154 **S***VCI*L**AF****VYFY*V*****IH*****H* 192
Rat 150 **S****C********S****FH*M*****IH*****H* 187>a
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EXPRESSION OF HUMAN CD80
region (amino acids 150 [Ile or Val] and 170 [Ile or Met]) and one (Fig. 3) that alters
the termination codon (TAA or TGA) .
Expression ofHuman CD8# mRNA .
￿
Expression of CD80 mRNA was examined
by Northern blot analysis (Fig. 4) . We could detect no CD80 mRNA in theT cell
leukemia lines HPB-ALL (Fig. 4, lane 1) orJM (Fig. 4, lane 2), although both of
these cell lines express CD8a mRNA and protein (Fig . 5 and data not shown) . It
should be noted that another line ofHPB-ALL has been reported to contain CD80
mRNA (17) . As has been previously observed (17), human thymus expresses alarge
amount of CD80 mRNA of -1.5 kb (Fig . 4, lane 3) . Most importantly, a 1.5-kb
CD80 transcript is also expressed in human PBMC (Fig. 4, lane 4) .
Expression ofHuman CD80 Protein on Transfected L Cells .
￿
To investigate whether
human CD80 could be expressed at the protein level, a full-length cDNA was sub-
cloned into an expression vector (pSFSVneo, reference 20) to yieldpSFSVn-HCD8p .
tk- L cells were transfected with pSFSVn-HCD8p alone, or pSFSVn-HCD80 and
an excess of the CD8a gene (pBR322/TK/CD8a, reference 12) . Transfectants were
selected by resistance to the antibiotic G418 . We were then presented with theproblem
ofhow to detect expression of the predicted human CD80 protein, since immuno-
precipitation studies of variously labeled populations ofhuman cell lines, PBL, and
thymocytes with standard anti-CD8 mAbs had failed to reveal a second subunit that
could correlate with this polypeptide chain . The mAbOKT5 had been described
FIGURE 4.
￿
Northern blot analysis of CD80mRNA expres-
sion. A Northern blot of total RNAfromHPB-ALL (lane
1),JM (lane 2), humanthymus (lane 3), andhumanPBMC
(lane 4) was hybridized to a "P-labeled human CD80
cDNA fragment .as binding to the same molecule as the anti-CD8 mAb OKT8, but to only a subset
ofOKT8+ cells (24-26), so we considered the possibility that its binding might re-
quire expression ofaCD80 chain. However, L cellstransfected withthe CD8a gene
alone stained positively with OKT5 (data not shown). In contrast, one putative
anti-human CD8mAbamongalarge panel examined failed tobind to Lcells trans-
fected with the isolated CD8a gene (27). This mAb, 2ST8-5117, was therefore poten-
tially specific either for the S chain ofCD8 or for a combinatorial determinant re-
quiringheterodimer formation between CD8a andCD80 chains. As reported (27),
2ST8-5117 did not bind to L cell transfectants expressing only CD8a (Fig. 5f), al-
though these cells did stain positively with mAb OKT8 (Fig. 5 e). Similarly, theHPB-
ALL (Fig. 5, a and b) andJM cell lines(datanot shown), which express only CD8a
mRNA (see above), stained only with OKT8 and not with 2ST8-5117. Transfec-
tants that received only the pSFSVn-HCD8D (CD8R) construct did not stain with
either OKT8 or 2ST8-5117 (Fig. 5, c and d), although these cells expressed CD80
SHIUE ET AL.
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FIGURE 5.
￿
Cell surface expression of CD8a andCD80
on cell linesandtransfectants. aandb, HPB-ALL;cand
d, L-HCD8S-A20, a cloned line of tk- L cells trans-
fected with theCD80 construct; eandf, L-HCD8a, tk-
Lcellscotransfected with the CD8a gene andtheik gene
andsorted forCD8a expression afterselection in HAT
medium; g andh, L-HCD8ap-P2, atwice-sorted pool
of tk- L cells transfected with both CD8a and CD80
constructs; iandj, L-HCD8ap-B4, acloned cell line de-
rived from L-HCD8aP-P2. Cellswere stained with ei-
ther OKT8 (a, c, e, g and i) or 2ST8-5117 (b, d, f, h,
and j), followed by fluorescein-conjugated goat
anti-mouse antibody. Dotted linesrepresentthenega-
tive controls, which were cells stained with the second
stage antibody alone. Forthosetransfectants receiving
both a and 0 constructs, the brightest 1% of cells
staining with 2ST8-5117 were sorted twice and then
cloned using the FAGS.2000
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mRNA (not shown). In contrast, transfectantsthat had received constructs encoding
both the a and R chains of CD8 stained positively both with OKT8 and 2ST8-5H7
(Fig. 5, g~jj). Transfectants receiving pSFSVn-HCD8p alone were cloned randomly
usingthe FAGS, and a cloned transfectant, L-HCD80-A20, expressing large amounts
of CD80 mRNA, was derived. When the CD8a gene was subsequently introduced
into this clone, the resultant population stainedpositively with both OKT8 and2ST8-
5H7 (datanotshown). These data indicate that cell surfacestaining with mAb2ST8-
5H7 requires expression of both the a and R chains of CD8. In the mouse system
we have previously shown that cell surface expression of the Ly-3 (CD8p) chain re-
quires the presence of Ly-2 (CD8a) (12), although Ly-2 can be expressed on the cell
surface as a homodimer in the absence of Ly-3 (10, 28). While it is likely that the
same situation holds true for humans, we cannot rule out the possibility that our
results reflect a specificity of mAb 2ST8-5H7 for a determinant unique to an a-0
heterodimer rather than merely pointing to the requirement of the a chain for cell
surface expression of the R chain. However, regardless ofwhether2ST8-5H7 recog-
nizes the a chain directly or only a-Q heterodimers, these results demonstrate the
existance of a CD80 protein that can be expressed on the cell surface of transfec-
tants, and further imply that this chain can complex with the CD8a chain.
We also transfected tk- L cells with a construct encoding the alternative CD80
chain that has alonger cytoplasmic tail sequence (Fig. 1 b), either alone or together
with the CD8a gene. The resultingtransfectants did not stain positively with 2ST8-
5H7 despite the presence of CD80 mRNA in the cells (data not shown), suggesting
that thepredicted alternative polypeptide chain cannot be expressedon thecell surface.
Expression ofHuman CD86 on the Surface Peripheral Blood TCells.
￿
With the knowl-
edge that aCD80 protein couldbe expressed, we examined thepresence of this pro-
tein chain in normal human peripheral blood cells to see whether the biologically
relevant form of CD8 might be a heterodimer in humans as it is in mice and rats.
We found that thedeterminantdefined by 2ST8-5H7 is indeed expressed on PBMC,
and that it is present only on OKT8+ (CD8a+ ) cells (Fig. 6). Approximately 17%
ofPBMC stained positively with OKT8 (Fig. 6 a), 16% stainedpositively with 2ST8-
5H7 (Fig. 6 b), and 16% with both mAbs (Fig. 6 c). The percentage of cells staining
positively with OKT8 wasconsistently slightly higher than that of cells staining posi-
tively with either 2ST8-5H7 alone or both mAbs. The population of cells that are
CD8a + and CD80 - comprises no more than 1% of PBMC. A small percentage of
the double positives seem to show a slightly reducedlevelof staining with 2ST8-5H7,
resulting in significant "shoulder" in the positive population (Fig. 6 c). This may
reflect a difference in subunit composition of heteromultimers, or it may be an indi-
cation that homodimers of the a chain exist as well. These data do not allow us to
conclude what proportion of CD8 molecules are a homodimers (orhomomultimers)
vs. a-R heterocomplexes.
Discussion
Biochemical studies ofthe subunitcomposition ofCD8in mice, rats, andhumans
indicatedsome surprising interspecies differences consideringthe similarities in both
function and cellular distribution of CD8 among these species. Mouse CD8 was
found to consist of two forms of disulfide-linked heterodimers (ap and a'D), while
one form of disulfide-linked heterodimer (aP) was identified in rat (8, 9, 13, 14).SHIUE ET AL .
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FIGURE 6 .
￿
Cell surface expression of CD8a and CD8D on
normal human PBMC . Normal human PBMC were stained
with (a) fluorescein-conjugated OKT8 (Ortho Diagnostic
Systems, Inc ., Westwood, MA) ; (b) 2ST8-5H7 and Texas
Red-conjugated goat anti-mouse antibody (Tago Inc., Burlin-
game, CA) ; (c) antibodies used in both a and b . Stainings were
performed sequentially in abuffer of 1 x PBS, 0.17o BSA, 0.02%
sodium azide, and 10% heat-inactivated rabbit serum . A
washing step with 25% normal mouse serum was also included
to block crossreactivity . Data are presented as 5% probability
contour plots . Large cells such as macrophages were eliminated
from the analysis by placing gates on the forward and obtuse
scatter,
In contrast, humanCD8 was believed to consist ofhomodimersand homomultimers
of a single (15, 16) chain equivalent to mouse CD8a (10, 11) . In the thymus, but
not in theperiphery, the higher multimersofhumanCD8 werefound to be disulfide
linked to a 46-kD CD1 glycoprotein (16, 29, 30) . CDl is aclass of molecules related
to class I MHC proteins, although they are encoded on a different chromosome
(31) . WhileCDl is typically associated noncovalently with R2-microglobulin (31, 32),
no R2-microglobulin has been found associated with the CD1 that is linked to CD8
in human thymus (29, 30) . Mouse and rat CD8 have not been described as being
associated with a CDl-equivalent protein in thymus .
Molecularbiological studies have nowresolved many of the discrepancies in CD8
structure in mice, rats, and humans . The a and a' chains of mouse CD8 (Ly-2a
and Ly-2a') havebeen shown to be products of alternatively spliced mRNA species
derived from a single CD8a gene (10, 28). The exclusion of sequence from exon IV
of this gene results in a frame-shift mutation, early termination, and production
ofa' protein . The a' chain differs from the achain (which contains exonIV sequence)
only in the cytoplasmic tail, which is four amino acids in length instead of 29 . A
human or rat equivalent of the a' chain has not been seen at the protein level, and2002
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we have not detected an equivalent alternatively spliced form ofhuman CD8 mRNA
(unpublished results). However, it is unlikely that the absence of a human or rat
CD8a'chain results in any functional difference in mature T cells. Severallaborato-
ries have found that very little a' chain is expressed on the surface of mouse periph-
eral T cells, despite the fact that thymocytes express close to equal amounts of cell
surface a and a' chains (9, 28, 33). We have recently demonstrated that this is a
result of a post-translational regulatory mechanism that blocks surface expression
of the a' chain in peripheral T cells and the most mature subset of CD8+, CD4-
thymocytes (33). While it is possible that the a' chain plays arole during thymocyte
development, it is clear that it is not an important molecule on mature mouse T
cells. Similarly, the absence of association ofmouseandrat CD8with CD1 on thymo-
cytes is not likely to be functionally significant, since the dimeric form of human
thymocyte CD8 also lacksCDl, and sinceCD1 is notexpressed on peripheral Tcells.
The final discrepancy between human and rodent CD8 is addressed by the data
presented here. No CD8ß (Ly-3 equivalent) chain has been identified as being as-
sociated with CD8a in biochemical studies of human CD8. However, we have re-
cently demonstrated that human CD8a, like its counterpart, can be used to rescue
cell surface expression of mouse CD8ß (12). These findings suggested that human
CD8a is indeed capable of associating with a ß chain. We have now shown that
mRNA encoding a CD8ß chain is expressed in both human thymus and PBMC,
and the sequences ofcDNA clones encoding this chaincontain an open readingframe.
We further found that a CD8ß chain could be expressed on the surface of L cells
transfected with a human CD8ß cDNA clone in an expression vector. Binding of
the mAb 2ST8-5H7 to transfectants required the presence of both a and ß chains
of CD8, either because the mAb binds to a conformational determinant that re-
quires the presence of both chains, becauseCD8a is required for surface expression
of CD8ß (as in the mouse system), or both. A second form of human CD8ß cDNA
could be shown to be the product of an alternatively spliced form of CD8ß mRNA
and to encode a protein with a longer cytoplasmic tail. However, a product of this
form of cDNA was not detected on the cell surface of transfected L cells, suggesting
that the encoded protein either fails to bind to CD8a or results in a complex that
is excluded from the cell surface. Finally, we demonstrated that human CD8ß is ex-
pressed on the surface of almost all PBMC that express CD8a. The small popula-
tion of cells (1%) that were positive for CD8a and negative for CD8ß could repre-
sent a different subset from the normal CD8+ T cells bearing aß TCRs; eg., they
could represent NK cells or another type of T cell. We conclude that the structure
of CD8 on peripheral blood T cells is essentially the same in mouse, rat, and man.
It is unclear why the presence ofthe CD8ß chain has not been demonstrated pre-
viously. Possibilities include inability to radiolabel well and/or comigration with the
a chain. If the latter is true, the CD8ß protein must contain a large amount of 0-
linked glycosylation, since the predicted molecular mass based on amino acid se-
quence is 21.4 kD and the sequence only predicts one site ofN-linked glycosylation.
Immunoprecipitation ofCD8 has in some cases yielded a broadband or two closely
spaced bands on onedimensional SDS-PAGE (15, 16, 34, 35), but protein sequencing
of the two bands of the CD8 doublet purified by Snow et al. (35) yielded a single
polypeptide sequence. It is possible that this resulted from a blocked NH2 terminus
of a closely migrating CD8ß chain, however, tryptic peptide mapping of the twoWe thank T Mak for the human thymocyte cDNA library, P Johnson for the rat CD8ß cDNA
probe and the human genomic subclone pß,4.3, E. Reinherz for mAb 2ST8-5H7, and A.
Koo for help in preparation of the manuscript.
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species were indistinguishable (35). Unfortunately, mAb 2ST8-5H7 has been found
not to immunoprecipitate any protein molecules from the surface of human PBL
(27). However, the availability of cDNA clones encoding CD80 should allow the
generation of new mAbs specific for this chain, and such mAbs could then be used
to determine the reason that human CD8ß has thus far not been identified as a pro-
tein band on a gel.
Gene transfer experiments with the mouse CD8a gene have demonstrated that
homodimers ofa and/or a' chains can perform at least some of the functions attrib-
uted to CD8, despite the fact that the physiological form of this protein is a hetero-
dimer containing a 0 chain (5-7). mAbs specific for the mouse 0 chain (as well as
those specific for the a chain) have been shown to inhibit cytotoxicity by mouse
CD8+ T cells (8, 36). It will be of great interest to determine in both mice and
humans whether the presence ofthe ß chain modifies or adds additional functional
properties to the CD8 molecule.
Summary
Human CD8 has been thought to consist of disulfide-linked homodimers and
homomultimers of a single polypeptide chain homologous to mouse and rat CD8a.
In contrast, mouse and rat CD8 are composed of disulfide-linked heterodimers of
a and ß chains. We have now isolated and sequenced cDNA clones encoding a human
homologue ofmouse and rat CD8ß . One such clone was inserted into an expression
vector and its encoded product was shown to be expressed on the cell surface after
cotransfection into L cells with the human CD8a gene. A second form of human
CD8ß cDNA encoding a protein with an altered cytoplasmic tail was similarly trans-
fected, but its product could not be demonstrated on the cell surface. CD8ß was
further shown to be expressed on the surface of almost all CD8+ human peripheral
blood T cells. These data provide the first evidence that human CD8 is a heterodi-
meric protein.
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